Equities

OncoCyte Corp

OncoCyte Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.86
  • Today's Change0.02 / 0.70%
  • Shares traded20.95k
  • 1 Year change+37.50%
  • Beta0.9811
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9.432037
Total Receivables, Net0.482.011.64
Total Inventory----0.30
Prepaid expenses0.640.980.69
Other current assets, total0.142.12--
Total current assets112639
Property, plant & equipment, net5.44118.53
Goodwill, net--019
Intangibles, net576291
Long term investments----0
Note receivable - long term------
Other long term assets0.460.370.26
Total assets75100160
LIABILITIES
Accounts payable0.951.252.45
Accrued expenses6.208.7310
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.121.42
Other current liabilities, total0.052.01--
Total current liabilities7.191214
Total long term debt000.12
Total debt00.121.53
Deferred income tax------
Minority interest------
Other liabilities, total424880
Total liabilities496094
SHAREHOLDERS EQUITY
Common stock310295253
Additional paid-in capital------
Retained earnings (accumulated deficit)(290)(261)(188)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.050.040.04
Total equity264065
Total liabilities & shareholders' equity75100160
Total common shares outstanding8.265.934.61
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.